| EBAC-ACCREDITED EDUCATIONAL PROGRAMMES |
| SATURDAY, May 26, 2012 |
| 12.40 – 14.10 |
Educational Programme (EBAC-Accredited ) |
T. Miettinen Hall |
| |
EBAC-Accredited Educational Programme, supported by an unrestricted educational grant from AstraZeneca |
| |
STRATEGIES FOR COMPREHENSIVE LIPID MANAGEMENT IN HIGH RISK PATIENTS Chairs:Alberico Catapano, Italy
Terje Pedersen, Norway |
| |
Welcome
Alberico Catapano Italy |
| |
Further reducing cardiovascular risk – what to target?
Julian Halcox, UK |
| |
Treatment challenges in patients with familial hypercholesterolaemia
Marcello Arca, Italy |
| |
Improving patient management – how implementation of the latest guidelines will help
Lale Tokgözoğlu, Turkey |
| |
Closing
Terje Pedersen, Norway | |
|
| EDUCATIONAL SYMPOSIA |
| SATURDAY, May 26, 2012 |
| 14:10- 15:00 |
Workshop |
S.O. Olofsson Hall |
| |
Sponsored by ROTTAPHARM | MADAUS |
| |
NUTRACEUTICALS FOR CARDIOVASCULAR PREVENTION: BRIDGING THE GAP BETWEEN LIFESTYLE THERAPEUTICAL CHANGES AND DRUG THERAPY
Chairs: Enzo Manzato, Italy
Luis Masana, Spain |
| |
Dyslipidemia and other risk factors management in low risk patients
Luis Masana, Spain |
| |
Alternative treatments in risk factors management
Bruno Trimarco, Italy |
| |
|
| 17.00-18.30 |
Educational Symposium |
T. Miettinen Hall |
| |
Sponsored by MSD |
| |
CLINICAL CONSIDERATIONS AND PRACTICAL APPROACHES TO MANAGING PATIENTS WITH DYSLIPIDEMIA
Chair: John Chapman, France |
| |
Unmet Medical Need in the Treatment of High Risk Populations
W. Virgil Brown, USA |
| |
Effective treatment options with add-on or combination therapy
Michel Farnier, France |
| |
Comprehensive Lipid Management: A Treatment Paradigm for Optimal Cardiovascular Risk Reduction
Dirk Müller, Germany |
| |
|
| 17.00-18.30 |
Educational Symposium |
S.O. Olofsson Hall |
| |
Sponsored by Genzyme |
| |
SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA AND THE POTENTIAL ROLE OF ANTISENSE TECHNOLOGY
Chair: Alberico Catapano, Italy |
|
Risk factors in severe heterozygous FH
Eric Bruckert, France |
|
Metabolic regulation of apoB-containing lipoproteins in severe heterozygous FH
Gerald F. Watts, Australia |
|
New treatment options in patients with severe heterozygous FH: applying antisense technology
Christie Ballantyne, USA |
|
Q&A and panel discussion
Alberico Catapano, Italy |
| |
|
| Sunday, May 27, 2012 |
| 12:40-14:10 |
Educational Symposium |
P. Avogaro Hall |
| |
Sponsored by Aegerion |
| |
NEW THERAPEUTIC APPROACHES FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Chairs: Cesare Sirtori Italy
John Chapman, France |
| |
Homozygous Familial Hypercholesterolemia: Pathophysiology, Genetics and Natural History
Robert Hegele, Canada |
| |
Current and novel treatment options for patients with severe FH
Dirk Blom, South Africa |
| |
MTP and MTP inhibition: a phase III study in patients with HoFH
Marina Cuchel, USA |
| |
|
| 14:10 – 14:55 |
Special Lecture |
S.O. Olofsson Hall |
| |
Sponsored by Sanofi\Regeneron |
| |
PCSK9 – a new target for reducing LDL Cholesterol
Evan Stein, USA |
| |
|
| 15:00 – 15:45 |
Special Lecture |
P. Avogaro Hall |
| |
Sponsored by CSL Behring |
| |
USE OF INFUSED HDL TO TREAT ACUTE CORONARY SYNDROME
Samuel D. Wright, USA |
| |
|
| 17:00 – 18:30 |
Educational Symposium |
T. Miettinen Hall |
| |
Sponsored by KOWA |
| |
PITAVASTATIN: NEW EFFECTIVE OPTION FOR MANAGING DYSLIPIDAEMIA WITH DIABETES OR HIGH CARDIOVASCULAR RISK Chair: Alberico Catapano, Italy |
| |
Managing dyslipidaemia complicated with diabetes or high cardiovascular risk: how well are we doing?
John Betteridge, UK |
| |
Pitavastatin for the management of dyslipidaemia and atherosclerosis
José-Ramon Gonzalez –Juanatey, Spain |
| |
Pitavastatin: addressing challenges: JAPAN-ACS and CIRCLE studies
Hidenori Arai, Japan |
| |
|
| 17:00 – 17:45 |
Special Lecture |
S.O. Olofsson Hall |
| |
Sponsored by MSD |
| |
CETP INHIBITION WITH ANACETRAPIB - IMPACT ON ATHEROGENIC LIPOPROTEINS
Chair: John Chapman, France |
| |
Welcome and Opening Remarks |
| |
The effect of anacetrapib on apoB metabolism
John Millar US |
| |
The effect of anacetrapib on Lipoprotein (a) metabolism
Gissette Reyes-Soffer US |
| |
Round table and Q&A |
| |
Closing remarks |